NeoGenomics, Inc.
16.59USD
+0.2000 (+1.22%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NEO.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 509.7M | 591.6M | 660.6M | 727.3M | 805.6M | 885.7M |
| Q1 | 117.2M | 137.2M | 156.2M | 168.0M | 186.7M | — |
| Q2 | 125.1M | 146.9M | 164.5M | 181.3M | 201.7M | — |
| Q3 | 128.8M | 152.0M | 167.8M | 187.8M | 207.3M | — |
| Q4 | 138.7M* | 155.6M* | 172.0M* | 190.2M* | 210.2M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.16 | -.701 | -.622 | -.843 | .187 | .343 |
| Q1 | -.400 | -.246 | -.215 | -.204 | -.132 | — |
| Q2 | -.285 | -.194 | -.147 | -.352 | .017 | — |
| Q3 | -.296 | -.147 | -.139 | -.211 | .055 | — |
| Q4 | -.183* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.114* |
| -.121* |
| -.077* |
| .070 |
| — |
Debt level and coverage